ALS LIMITED — M&A Activity 2019

Aug 7, 2019

==> picture [180 x 69] intentionally omitted <==

asx/media release

8 August 2019

ALS acquires market-leading Latin American pharmaceutical testing business

ALS Limited (ASX Code: ALQ) today announced the acquisition of Laboratorios de Control ARJ S.A de C.V (‘ARJ’).

ARJ is based in Mexico City, Mexico and is the largest private pharmaceutical testing laboratory in Latin America with revenues of over $30 million. Founded in 1967 and employing over 500 people, ARJ specialises in providing quality control for medicines, biological products, generics, biosimilars, cosmetics and medical devices and services many of the largest global pharmaceutical companies.

Mexico is a growing part of the $20 billion global pharmaceutical testing market and an important hub for Latin and North America. ARJ will complement the existing ALS Life Sciences Latin America operations and is expected to benefit from Group’s regional and global presence to further expand their offering to clients.

Commenting on the transaction, ALS Managing Director and CEO Raj Naran said “this is an important, strategic acquisition for us. ARJ has a world class operation and client base which offers us a strong platform to continue to grow our presence in key markets including Argentina, Brazil, Colombia, and Mexico. We welcome the ARJ team to ALS and look forward to our collaboration with them throughout the region.”

“The acquisition of ARJ aligns with our stated acquisition strategy focusing on food and pharmaceutical opportunities in key growth markets such as Latin America. It also supports our 2022 strategic plan of growing our non-cyclical businesses within the Group.”

-ENDS-

Further information: Raj Naran

Managing Director & CEO ALS Limited +61 (7) 3367 7900

About ALS Limited

ALS is a global Testing, Inspection & Certification business. The company's strategy is to broaden its exposure into new sectors and geographies where it can take a leadership position.